Therapeutic angiogenesis

Vascular and Endovascular Surgery

Volumn 41, Issue 3, 2007, Pages 173-185

  Vartanian, Shant M ^a   Sarkar, Rajabrata ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ischemia; Molecular therapy; Neovascularization; Therapeutic angiogenesis

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR; LIPOSOME; PLACEBO; PLASMID VECTOR; VASCULOTROPIN;

ANGINA PECTORIS; ANGIOGENESIS; CAPILLARY; CAPILLARY DENSITY; CLAUDICATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIA; LIMB ISCHEMIA; LOW DRUG DOSE; MONOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RABBIT; REVIEW; STEM CELL; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANIMALS; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIALS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; HUMANS; INTERMITTENT CLAUDICATION; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; PHARMACOGENETICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250861363     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574407302849     Document Type: Review

References (59)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 ; 113: e85 - e151.
2. Feinglass J., Brown JL, LoSasso A., et al. Rates of lower-extremity amputation and arterial reconstruction in the United States, 1979 to 1996. Am J Public Health. 1999 ; 89: 1222-1227.
3. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003 ; 289: 76-79.
4. Sabia PJ, Powers ER, Ragosta M., Sarembock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992 ; 327: 1825-1831.
5. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 ; 86: 353-364.
6. Tammela T., Enholm B., Alitalo K., Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005 ; 65: 550-563.
7. Gerhardt H., Golding M., Fruttiger M., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003 ; 161: 1163-1177.
8. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 ; 359: 843-845.
9. Roberts WG, Palade GE Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995 ; 108 (Pt 6). 2369-2379.
10. Presta M., Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005 ; 16: 159-178.
11. Seghezzi G., Patel S., Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998 ; 141: 1659-1673.
12. Ribatti D., Nico B., Morbidelli L., et al. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. J Vasc Res. 2001 ; 38: 389-397.
13. Scholz D., Ito W., Fleming I., et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch. 2000 ; 436: 257-270.
14. Ito WD, Arras M., Winkler B., Scholz D., Schaper J., Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 1997 ; 80: 829-837.
15. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002 ; 8: 831-840.
16. Fujii T., Yonemitsu Y., Onimaru M., et al. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization: critical role of the inflammatory/arteriogenic pathway. Arterioscler Thromb Vasc Biol. 2006 ; 26: 2483-2489.
17. Deindl E., Hoefer IE, Fernandez B., et al. Involvement of the fibroblast growth factor system in adaptive and chemokineinduced arteriogenesis. Circ Res. 2003 ; 92: 561-568.
18. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999 ; 5: 434-438.
19. Ziegelhoeffer T., Fernandez B., Kostin S., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004 ; 94: 230-238.
20. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996 ; 380: 435-439.
21. Asahara T., Takahashi T., Masuda H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999 ; 18: 3964-3972.
22. Yanagisawa-Miwa A., Uchida Y., Nakamura F., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992 ; 257: 1401-1403.
23. Takeshita S., Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 1994 ; 90: 11228-11234.
24. Isner JM Myocardial gene therapy. Nature. 2002 ; 415: 234-239.
25. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972 ; 136: 261-276.
26. Khurana R., Simons M., Martin JF, Zachary, IC Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation. 2005 ; 112: 1813-1824.
27. Masaki I., Yonemitsu Y., Tanii M., et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res. 2002 ; 90: 966-973.
28. Kamba T., Tam BY, Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006 ; 290: H560 - H576.
29. Cooper LT Jr, Hiatt WR, Creager MA, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med. 2001 ; 6: 235-239.
30. Isner JM, Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996 ; 348: 370-374.
31. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 ; 97: 1114-1123.
32. Makinen K., Manninen H., Hedman M., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther. 2002 ; 6: 127-133.
33. Kusumanto YH, van Weel V., Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006 ; 17: 683-691.
34. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 2002 ; 359: 2053-2058.
35. Rajagopalan S., Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003 ; 108: 1933-1938.
36. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF 121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 ; 100: 468-474.
37. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998 ; 98: 2800-2804.
38. Simons M., Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002 ; 105: 788-793.
39. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003 ; 107: 1359-1365.
40. Hedman M., Hartikainen J., Syvanne M., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003 ; 107: 2677-2683.
41. Kastrup J., Jorgensen E., Ruck A., et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol. 2005 ; 45: 982-988.
42. Gyongyosi M., Khorsand A., Zamini S., et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation. 2005 ; 112: 1157-1165.
43. Grines CL, Watkins MW, Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002 ; 105: 1291-1297.
44. Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003 ; 42: 1339-1347.
45. Schiekofer S., Galasso G., Sato K., Kraus BJ, Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1603-1609.
46. van Weel V., de Vries M., Voshol PJ, et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol. 2006 ; 26: 1383-1390.
47. Palmer-Kazen U., Wariaro D., Luo F., Wahlberg E. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. J Vasc Surg. 2004 ; 39: 621-628.
48. Liu TJ, Lai HC, Ting CT, Lee WL Sustained elevation of circulating vascular endothelial growth factor after percutaneous angioplasty for peripheral arterial diseases. Int J Cardiol. 2006 ; 107: 415-416.
49. Yla-Herttuala S., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 2003 ; 9: 694-701.
50. Jiao S., Williams P., Berg RK, et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther. 1992 ; 3: 21-33.
51. Freedman SB, Vale P., Kalka C., et al. Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther. 2002 ; 13: 1595-1603.
52. Vogeli KM, Jin SW, Martin GR, Stainier DY A common progenitor for haematopoietic and endothelial lineages in the zebrafish gastrula. Nature, 2006 ; 443: 337-339.
53. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999 ; 85: 221-228.
54. Badorff C., Brandes RP, Popp R., et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation. 2003 ; 107: 1024-1032.
55. Assmus B., Schachinger V., Teupe C., et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002 ; 106: 3009-3017.
56. Schachinger V., Assmus B., Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J Am Coll Cardiol. 2004 ; 44: 1690-1699.
57. Tateno K., Minamino T., Toko H., et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res. 2006 ; 98: 1194-1202.
58. Meyer GP, Wollert KC, Lotz J., et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006 ; 113: 1287-1294.
59. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001 ; 89: E1 - E7.